EssilorLuxottica CEO says shares will recover lost ground By Investing.com

EssilorLuxottica shares are still down more than 40% from their November record high, but CEO Francesco Milleri said the stock should recover after the company completes its medtech transformation. He cited headwinds from U.S. tariffs, dollar weakness, military conflicts and rising competition in smart eyeglasses, while arguing that no true competing products are yet on the market. The commentary is more about long-term positioning than near-term fundamentals, so the immediate market impact should be limited.

Analysis

The market is treating EssilorLuxottica less like a defensive consumer-health compounder and more like a proxy for whether the smart-eyewear category can become a platform business. That re-rating matters because the next leg is likely not driven by unit growth alone, but by ecosystem control: whoever owns the device, app layer, and distribution can extract far more value than the underlying eyewear margin suggests. The current selloff looks like positioning unwinds after a narrative peak, not necessarily a deterioration in core economics.

The second-order risk is that the medtech pivot creates an awkward capital allocation transition: investors are being asked to underwrite a lower-visibility transformation while the prior growth engine is still being pressure-tested by competition and product-cycle fatigue. In that setup, any delay in smart-glasses adoption can hit the stock twice — once through sentiment, and again through multiple compression as the market discounts the medtech story as a longer-dated option rather than a near-term earnings driver. The likely time horizon for stabilization is months, not days, unless a new product cycle or channel data shows clear acceleration.

For META, the issue is not near-term revenue leakage but bargaining power. If eyewear becomes a meaningful interface for AI assistants, Meta benefits from being the default software layer, while the hardware partner absorbs more of the manufacturing and inventory risk. The contrarian view is that the market may be overestimating competitive threat from announced products and underestimating the moat created by distribution, brand trust, and developer integration — but that moat only matters if consumers actually replace phones for some use cases, which remains a multi-year adoption curve.

The cleanest trade is to stay cautious on the stock until the market gets proof of execution rather than management reassurance. The setup favors tactical patience over aggressive dip-buying: if the category is real, there will be a better entry on a pullback after the next product or channel checkpoint; if it is not, the stock likely remains a multiple trap. This is the kind of transition story where the fastest money is usually made in the confirmation window, not during the first phase of narrative repair.

Key Decisions for Investors

• Avoid chasing the rebound in ESLX/EssilorLuxottica immediately; wait for 1-2 quarters of evidence that smart-eyewear sell-through is accelerating before adding risk. If the stock retraces another 10-15%, that is a better entry for a medium-term mean reversion trade.
• Pair trade: long META vs short a basket of hardware-dependent consumer-device names that lack platform control, for a 3-6 month horizon. If smart eyewear becomes real, the software owner should retain more economics than the OEM layer.
• Sell covered calls against any ESLX long exposure into volatility spikes; the stock likely trades sideways-to-down until the market has proof that medtech and AI eyewear can both contribute to earnings. This monetizes time decay while limiting downside participation.
• For event-driven traders, buy a small dated call spread on META into the next product-cycle catalyst; the asymmetric upside is in software monetization, not hardware margin, but keep sizing modest because adoption is still early-stage.
• Watch for channel checks on competing smart-glasses launches over the next 1-2 quarters; if actual retail availability remains weak, consider a tactical long in ESLX on a 15-20% drawdown as the competitive overhang may be overstated.